Fig 4. Intermittent PLX5622 administration during scrapie infection.

A. Cartoon showing the different treatment groups. B. Survival curves following infection with 22L scrapie. Mice were untreated or treated with PLX5622 for either one week, two weeks or three weeks as described in panel A. No differences were seen between any of the groups (Mantel-Cox, Log-rank test). Each survival group contained 9–11 mice. C, D, E. Iba1 positive cell or pixel count comparisons in thalamus (C), cortex (D) or whole brain (E) between untreated (ND) and PLX5622 treated (PLX) mice at 87, 108 and 129 dpi. These time points were selected to correspond with cessation of PLX5622 treatment in the three different PLX treatment groups. Untreated and PLX5622 treated mice were compared using an unpaired T-test for each experimental pair. Only the uninfected, PLX5622 treated mice were significantly different than untreated, uninfected mice. The uninfected PLX5622 treated mice were included only as a drug efficacy control and were treated with PLX5622 for 19 days concurrent with the time period of the scrapie infected PLX5622 treated mice, using the same lot of medicated feed.